Title of the program A Medical Need Program of Inotuzumab Ozogamicin for the treatment of adult patients with relapsed or refractory (R/R) CD22-. • Besponsa carries a boxed warning for hepatotoxicity, including hepatic veno-occlusive disease, and increased risk of post-hematopoietic stem cell transplant non-relapse mortality. • Other warnings and precautions of Besponsa include myelosuppression, infusion related reactions,. We would like to show you a description here but the site won’t allow us.. Antibodies 2018, 7, 6 2 of 17 Although there has been a recent shift towards site-speciﬁc conjugation methods through engineered cysteines or enzymatic linkage, lysine conjugates still account for ~25% of ADCs currently in clinical. . .